Pharmanovia Enters Into an Exclusive Licensing Agreement With Aeterna Zentaris for the First and Only Orally Administered Approved Medicine for the Diagnosis of Growth Hormone Deficiency in Adults
The Agreement Covers the European Economic Area (EEA) and the UK Pharmanovia Will Take Over Rights From Consilient Health and Any Future European Commercial Rights for Paediatric Indications Resulting
Source: finanznachrichten.de